Int J Infect Dis . Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nation-wide Consortium to Investigate Host Genetics of COVID-19

[tetano]

Int J Infect Dis


. 2021 Sep 30;S1201-9712(21)00775-X.
doi: 10.1016/j.ijid.2021.09.070. Online ahead of print.
Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nation-wide Consortium to Investigate Host Genetics of COVID-19


Hiromu Tanaka ¹ , Ho Lee ¹ , Atsuho Morita ¹ , Ho Namkoong ² , Shotaro Chubachi ¹ , Hiroki Kabata ¹ , Hirofumi Kamata ¹ , Makoto Ishii ¹ , Naoki Hasegawa ² , Norihiro Harada ³ , Tetsuya Ueda ⁴ , Soichiro Ueda ⁵ , Takashi Ishiguro ⁶ , Ken Arimura ⁷ , Fukuki Saito ⁸ , Takashi Yoshiyama ⁹ , Yasushi Nakano ¹⁰ , Yoshikazu Mutoh ¹¹ , Yusuke Suzuki ¹² , Koji Murakami ¹³ , Yukinori Okada ¹⁴ , Ryuji Koike ¹⁵ , Yuko Kitagawa ¹⁶ , Katsushi Tokunaga ¹⁷ , Akinori Kimura ¹⁸ , Seiya Imoto ¹⁹ , Satoru Miyano ²⁰ , Seishi Ogawa ²¹ , Takanori Kanai ²² , Koichi Fukunaga ¹ , Japan COVID-19 Task Force



Affiliations

• PMID: 34601141
• DOI: 10.1016/j.ijid.2021.09.070

Abstract

Background and design: The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19. The Japan COVID-19 Task Force is conducting host genome analysis of hospitalized patients with COVID-19 from more than 70 institutions nationwide in Japan. This report describes the clinical characteristics of patients enrolled to date.
Results: The median (interquartile range) age of the 1674 patients included in the analysis was 59 (45-71) years, and more than half of the patients (66.2%) were male. Less than half of the patients (41.2%) had severe disease. The case fatality rate was 3.2%.
Conclusions: Since this is a hospital-based study, the number of severe cases was relatively high, but the case fatality rate was relatively low, when compared to that of other countries. In the future, we will continue to enroll patients and conduct genome analyses of patients with COVID-19.

Keywords: COVID-19; Clinical character; Host genetics; Japan; Pneumonia.